E2 ModeratePreliminaryPEM unclearCase-ControlPeer-reviewedMachine draft
A 37 kDa 2-5A binding protein as a potential biochemical marker for chronic fatigue syndrome.
De Meirleir, K, Bisbal, C, Campine, I et al. · The American journal of medicine · 2000 · DOI
Quick Summary
Researchers found a specific protein (37 kDa) in the blood cells of 88% of ME/CFS patients, compared to only 28% of control subjects. This protein was present in much higher amounts in ME/CFS patients, suggesting it could potentially be used as a blood test to help identify the condition.
Why It Matters
A reliable biochemical marker could improve ME/CFS diagnosis, which currently relies on clinical criteria alone. This finding supports evidence of measurable immune system abnormalities in ME/CFS and suggests biological mechanisms may underlie the condition.
Observed Findings
- 37 kDa protein present in 50 of 57 (88%) ME/CFS patients versus 15 of 53 (28%) controls (p < 0.01)
- 37 kDa/80 kDa protein ratio >0.05 found in 72% of ME/CFS patients versus 11% of healthy controls and 0% of depression/fibromyalgia patients
- When present in controls, the 37 kDa protein was detected in very low amounts
- Blinded study design with comparison between ME/CFS, healthy, depression, and fibromyalgia groups
Inferred Conclusions
- The 37 kDa 2-5A binding protein may distinguish ME/CFS patients from healthy subjects and those with other conditions
- Abnormalities in the ribonuclease L pathway appear characteristic of ME/CFS compared to other disease states
- This protein could serve as a potential biochemical marker for ME/CFS diagnosis
Remaining Questions
- Does the presence of this protein predict disease severity or prognosis?
- Is the 37 kDa protein abnormality stable over time or does it fluctuate with symptom changes?
- What is the functional role of this protein in ME/CFS pathophysiology?
- Can these findings be replicated in larger, geographically diverse patient populations?
What This Study Does Not Prove
This study does not prove the 37 kDa protein causes ME/CFS—it only shows an association. The study cannot establish whether this protein is a consequence of the disease or a contributing factor, and findings require replication in larger, independently verified populations before clinical diagnostic use.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory OnlyMixed Cohort
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →